Immunome 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AL101 / Immunome
2020-001979-33: A study of investigational medicinal product AL101 in adults with breast cancer

Not yet recruiting
2
73
Europe
AL101, Solution for infusion
Ayala Pharmaceuticals, Inc., Ayala Pharmaceuticals, Inc.
Notch Activated Recurrent or Metastatic Triple Negative Breast Cancer, Breast cancer, Diseases [C] - Cancer [C04]
 
 
2019-000309-64: A study of investigational medicinal product AL101 in adults who have adenoid cystic carcinoma, and a specific genetic alteration in a gene called Notch, that has come back or did not get better with a previous therapy

Not yet recruiting
2
87
Europe
AL101, Concentrate for solution for infusion
Ayala Pharmaceuticals, Inc., Ayala Pharmaceuticals, Inc.
Adenoid cystic carcinoma, Adenoid cystic carcinoma is a rare type of cancer that can affect many different body sites, Diseases [C] - Cancer [C04]
 
 
ACCURACY, NCT03691207 / 2019-000309-64: A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

Completed
2
87
Europe, Canada, US, RoW
AL101, BMS 906024
Ayala Pharmaceuticals, Inc,, Ayala Pharmaceuticals, Inc.
Adenoid Cystic Carcinoma
07/22
12/22
TENACITY, NCT04461600 / 2020-001979-33: A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

Terminated
2
18
Europe, US, RoW
AL101
Ayala Pharmaceuticals, Inc,, Ayala Pharmaceuticals, Inc.
Triple Negative Breast Cancer
03/22
10/22
NCT04973683: AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Active, not recruiting
1
14
US
AL101, AL 101, AL-101, BM-0018, BM0018, BMS-906024, GS/pan-Notch Inhibitor AL101, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
12/25
12/25
varegacestat (AL102) / Immunome
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
NCT06677996: A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants

Active, not recruiting
1
22
US
varegacestat, Itraconazole (200 mg)
Immunome, Inc.
Healthy Volunteer
12/24
04/25
NCT06845852: A Phase 1 Mass Balance Study of Varegacestat

Recruiting
1
6
US
varegacestat
Immunome, Inc.
Healthy Volunteer
07/25
07/25
NCT06841315: A Varegacestat Hepatic Impairment Study

Recruiting
1
44
US
varegacestat
Immunome, Inc.
Healthy Volunteer, Hepatic Impairment (HI)
11/25
12/25
NCT06855264: A Cardiac Liability Study of Varegacestat in Healthy Participants

Recruiting
1
32
US
varegacestat, Placebo, Moxifloxacin 400 mg
Immunome, Inc.
Healthy Volunteer
06/25
08/25
IMM-BCP-01 / Immunome
NCT05429021: IMM-BCP-01 in Mild to Moderate COVID-19

Terminated
1
9
US
IMM-BCP-01, Placebo
Immunome, Inc., United States Department of Defense
SARS-CoV2 Infection, COVID-19
01/23
01/23
IM-4320 / Immunome
No trials found
IMM20059 / Immunome
No trials found
Undisclosed cancer therapeutic / AbbVie, Immunome
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AL101 / Immunome
2020-001979-33: A study of investigational medicinal product AL101 in adults with breast cancer

Not yet recruiting
2
73
Europe
AL101, Solution for infusion
Ayala Pharmaceuticals, Inc., Ayala Pharmaceuticals, Inc.
Notch Activated Recurrent or Metastatic Triple Negative Breast Cancer, Breast cancer, Diseases [C] - Cancer [C04]
 
 
2019-000309-64: A study of investigational medicinal product AL101 in adults who have adenoid cystic carcinoma, and a specific genetic alteration in a gene called Notch, that has come back or did not get better with a previous therapy

Not yet recruiting
2
87
Europe
AL101, Concentrate for solution for infusion
Ayala Pharmaceuticals, Inc., Ayala Pharmaceuticals, Inc.
Adenoid cystic carcinoma, Adenoid cystic carcinoma is a rare type of cancer that can affect many different body sites, Diseases [C] - Cancer [C04]
 
 
ACCURACY, NCT03691207 / 2019-000309-64: A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

Completed
2
87
Europe, Canada, US, RoW
AL101, BMS 906024
Ayala Pharmaceuticals, Inc,, Ayala Pharmaceuticals, Inc.
Adenoid Cystic Carcinoma
07/22
12/22
TENACITY, NCT04461600 / 2020-001979-33: A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

Terminated
2
18
Europe, US, RoW
AL101
Ayala Pharmaceuticals, Inc,, Ayala Pharmaceuticals, Inc.
Triple Negative Breast Cancer
03/22
10/22
NCT04973683: AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Active, not recruiting
1
14
US
AL101, AL 101, AL-101, BM-0018, BM0018, BMS-906024, GS/pan-Notch Inhibitor AL101, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
12/25
12/25
varegacestat (AL102) / Immunome
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
NCT06677996: A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants

Active, not recruiting
1
22
US
varegacestat, Itraconazole (200 mg)
Immunome, Inc.
Healthy Volunteer
12/24
04/25
NCT06845852: A Phase 1 Mass Balance Study of Varegacestat

Recruiting
1
6
US
varegacestat
Immunome, Inc.
Healthy Volunteer
07/25
07/25
NCT06841315: A Varegacestat Hepatic Impairment Study

Recruiting
1
44
US
varegacestat
Immunome, Inc.
Healthy Volunteer, Hepatic Impairment (HI)
11/25
12/25
NCT06855264: A Cardiac Liability Study of Varegacestat in Healthy Participants

Recruiting
1
32
US
varegacestat, Placebo, Moxifloxacin 400 mg
Immunome, Inc.
Healthy Volunteer
06/25
08/25
IMM-BCP-01 / Immunome
NCT05429021: IMM-BCP-01 in Mild to Moderate COVID-19

Terminated
1
9
US
IMM-BCP-01, Placebo
Immunome, Inc., United States Department of Defense
SARS-CoV2 Infection, COVID-19
01/23
01/23
IM-4320 / Immunome
No trials found
IMM20059 / Immunome
No trials found
Undisclosed cancer therapeutic / AbbVie, Immunome
No trials found

Download Options